JP2022517920A5 - - Google Patents
Info
- Publication number
- JP2022517920A5 JP2022517920A5 JP2021538762A JP2021538762A JP2022517920A5 JP 2022517920 A5 JP2022517920 A5 JP 2022517920A5 JP 2021538762 A JP2021538762 A JP 2021538762A JP 2021538762 A JP2021538762 A JP 2021538762A JP 2022517920 A5 JP2022517920 A5 JP 2022517920A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- antibody
- domain
- protein according
- target fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910023522.6A CN111423512B (zh) | 2019-01-10 | 2019-01-10 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| CN201910023522.6 | 2019-01-10 | ||
| PCT/CN2020/071213 WO2020143720A1 (zh) | 2019-01-10 | 2020-01-09 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022517920A JP2022517920A (ja) | 2022-03-11 |
| JP2022517920A5 true JP2022517920A5 (cg-RX-API-DMAC10.html) | 2024-03-12 |
Family
ID=71521813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538762A Ceased JP2022517920A (ja) | 2019-01-10 | 2020-01-09 | 血管内皮細胞の増殖をブロックし、t細胞を活性化する多標的融合タンパク質、およびそれを含有する医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220106389A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3909986A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2022517920A (cg-RX-API-DMAC10.html) |
| CN (1) | CN111423512B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020143720A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191201A1 (ru) | 2018-12-03 | 2022-01-26 | Эдженсис, Инк. | Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения |
| WO2021185337A1 (zh) * | 2020-03-20 | 2021-09-23 | 荣昌生物制药(烟台)股份有限公司 | 一种双特异性融合蛋白及其应用 |
| US20230235011A1 (en) * | 2020-05-25 | 2023-07-27 | Beijing Beyond Biotechnology Co., Ltd | Fc-cd80 fusion protein and conjugates thereof and their uses |
| EP4205763A4 (en) * | 2020-08-27 | 2025-01-01 | Shanghai Junshi Biosciences Co., Ltd. | Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma |
| CN115947793B (zh) * | 2021-08-13 | 2023-09-26 | 中国人民解放军总医院 | 靶向pd-l1的超高亲和力小蛋白及用途 |
| CN119136822A (zh) * | 2022-03-04 | 2024-12-13 | 帕诺洛斯生物科技有限公司 | 包括VEGF-Grab和PD-1或PD-L1拮抗剂的联合治疗组合物 |
| IL318220A (en) * | 2022-07-25 | 2025-03-01 | Agensys Inc | Methods for treating patients with locally advanced or metastatic urinary tract cancer with antibody drug conjugates (ADCs) that bind 191P4D12 proteins in combination with pembrolizumab |
| CN119654343A (zh) * | 2022-08-09 | 2025-03-18 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
| WO2024055996A1 (zh) * | 2022-09-14 | 2024-03-21 | 寻济生物科技(北京)有限公司 | 一种抗vegfa抗体或其抗原结合片段及其应用 |
| CN116102624B (zh) * | 2023-03-07 | 2025-10-03 | 南京中医药大学 | 一种具有抑制血管生成作用的线性多肽及其环肽 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1916001E (pt) * | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
| EP1877438A2 (en) | 2005-02-02 | 2008-01-16 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| WO2010136480A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| RU2567639C2 (ru) * | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2646007B1 (en) * | 2010-12-02 | 2016-12-21 | Neurotech USA, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
| BR112014013205A2 (pt) * | 2011-12-01 | 2020-10-27 | Protevobio, Inc. | proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit |
| UA122479C2 (uk) * | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CN104195173B (zh) | 2014-09-02 | 2017-03-08 | 北京比洋生物技术有限公司 | 具有双表达盒的谷氨酰胺合成酶高效表达载体 |
| BR112018000366A2 (pt) * | 2015-08-07 | 2018-09-11 | Pieris Pharmaceuticals Gmbh | polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão |
| CA3001131A1 (en) * | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| CN109069638B (zh) * | 2016-03-24 | 2022-03-29 | 璟尚生物制药公司 | 用于癌症治疗的三特异性抑制剂 |
| CA3026518A1 (en) * | 2016-06-17 | 2017-12-21 | Genentech, Inc. | Purification of multispecific antibodies |
| MX2019010887A (es) * | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| CN108623691B (zh) * | 2017-03-17 | 2020-05-15 | 北京比洋生物技术有限公司 | IgG样长效免疫融合蛋白及其应用 |
| MY200973A (en) * | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
-
2019
- 2019-01-10 CN CN201910023522.6A patent/CN111423512B/zh active Active
-
2020
- 2020-01-09 US US17/421,874 patent/US20220106389A1/en not_active Abandoned
- 2020-01-09 EP EP20738951.1A patent/EP3909986A4/en not_active Withdrawn
- 2020-01-09 WO PCT/CN2020/071213 patent/WO2020143720A1/zh not_active Ceased
- 2020-01-09 JP JP2021538762A patent/JP2022517920A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6124377B2 (ja) | 新規抗dr5抗体 | |
| JP7196076B2 (ja) | がんの処置のための抗tnf関連アポトーシス誘発リガンド受容体2及び抗カドヘリン17結合性二重特異的分子 | |
| JP2024125370A (ja) | クローディン18.2結合部分およびその利用 | |
| AU2015210420B2 (en) | Anti c-Met antibodies | |
| DK2758073T3 (en) | VEGF / DLL4 BINDING AGENTS AND APPLICATIONS THEREOF | |
| JP2021526816A (ja) | Dll3−cd3二重特異性抗体 | |
| JP2022515318A5 (cg-RX-API-DMAC10.html) | ||
| KR20120024763A (ko) | 항axl 항체 | |
| JP2018502050A5 (cg-RX-API-DMAC10.html) | ||
| CA2706425A1 (en) | Method for obtaining polypeptide constructs comprising two or more single domain antibodies | |
| JP2013515508A5 (cg-RX-API-DMAC10.html) | ||
| JP2024001073A5 (cg-RX-API-DMAC10.html) | ||
| US20250051467A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| CA3208455A1 (en) | Novel anti-gremlin1 antibodies | |
| JP2022521305A (ja) | 抗pd-l1抗体及びその使用 | |
| JP2023531672A (ja) | H2L2とHCAb構造を有する結合タンパク質 | |
| JP2024517953A (ja) | アルファ5ベータ1インテグリン結合剤及びその使用 | |
| JP2026505164A (ja) | 抗cmet抗体及びその使用方法 | |
| CN120271715A (zh) | 抗体及其药物偶联物和用途 | |
| CA3119458A1 (en) | Methods and monitoring of treatment with vegf/dll4 binding agent | |
| TW202328186A (zh) | 抗her2抗體及其使用方法 | |
| JP2024508597A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2016163433A1 (ja) | 抗fgfr2抗体と他剤を含む組成物 | |
| WO2026067461A1 (en) | Multispecific antibody protein and uses thereof | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof |